What You Should Know:
- Today, Medisafe, a leading digital therapeutics and patient engagement company launches its new Digital Document Exchange module to streamline the medication approval process.
- The solution enables patients to upload and submit required documentation directly through the company's app — speeding complex medication approval processes from an average of 24 days to 10 minutes and allowing patients to begin treatment therapy sooner.
Digital Document Exchange
Read More
Digital Therapeutics | Digital Health | Evidence-Based Therapeutics Interventions
Pear Therapeutics Acquires 2 Depression Assets to Optimize Depression Product Candidate
What You Should Know:
- Pear Therapeutics, Inc. (Nasdaq: PEAR), announced it has acquired two new digital therapeutic assets that it intends to integrate into a potential prescription digital therapeutic (PDT) to treat patients across a continuum of depression subtypes and severities.
- Additionally, Pear announced yesterday the expansion of its existing initiative with Crossroads. Through this expansion, Pear’s PDTs, reSET® and reSET-O®, have the potential to reach thousands of additional
Read More
Commercializing Digital Therapeutic Solutions: Key Lessons Learned to Watch
The pandemic has set ablaze the white-hot market for Digital Therapeutics (DTx), which “deliver medical interventions directly to patients using evidence-based, clinically evaluated software to treat, manage, and prevent a broad spectrum of diseases and disorders1.” In 2020, a digital research firm projected the global DTx market to hit nearly $9 billion by 2025; a year later, its 2025 DTx forecast had increased to $56 billion2.
One of the few bright spots of 2020 was how quickly and
Read More
MindMaze Secures $125M to Accelerate Commercialization of Digital Neurotherapeutics Platform
What You Should Know:
- MindMaze, a SaaS-based digital neurotherapeutics platform raises $125M led by AlbaCore Capital Group, one of Europe's leading specialist investors focusing on public and private corporate credit markets. MindMaze delivers seamless digital assessments and therapeutics over the full continuum of care in over twenty countries, with thousands of patients suffering from neurological conditions.
- MindMaze will use the proceeds to accelerate commercialization of and
Read More
Neuroglee Raises $10M to Develop Virtual Neurology Clinics with Mayo Clinic, Others
What You Should Know:
- Neuroglee, a Boston, MA-based provider of personalized evidence-based digital therapeutics (DTx) and virtual care solutions, today announced it has raised $10M in Series A funding led by OpenSpace Ventures with participation by EDBI.
- Neuroglee Therapeutics discovers, develops and commercializes personalized evidence-based digital therapeutics (DTx) and virtual care solutions to treat and manage patients with neurodegenerative diseases. Neuroglee’s adaptive
Read More
Why Healthcare Innovation Needs Human-Centered Principles
Millions of people around the world have lost their health as a result of the pandemic. Millions more have lost loved ones. Trillions of dollars have been spent fighting the virus and restoring life post-pandemic, while many families have lost income, savings, or both.
COVID-19 has no doubt been catastrophic, but let it also be the wake-up call we need to improve experiences for both patients and healthcare providers alike. In a new era increasingly shaped by remote care, digital tools,
Read More
Biofourmis Earns FDA Breakthrough Device Designation for Digital Therapeutic for Heart Failure
What You Should Know:
- Biofourmis, a Boston-based global leader in virtual care and digital therapeutics, announced its BiovitalsHF® solution is the first-ever heart failure digital therapeutic to receive a Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
- The Breakthrough Devices Program was created to provide patients and providers with timely access to medical devices (in this case, software as a medical device, or SaMD) by speeding up their
Read More
TRIPP Secures $11M to Expand Digital Psychedelic Wellness Platform for Mental Health
What You Should Know:
- TRIPP, a Los Angeles-based digital psychedelic platform, announced it has raised $11M in funding led by Vine Ventures, and Mayfield with equal participation from Integrated. TRIPP’s Series A also includes particpation from AlphaBridge Ventures, Beni VC, Berkeley Club, CJ Group, CTR Capital, Evolution, Robert Goldberg, Tony Greenberg, Grit VC, Incisive Ventures, Inflect Health, Iter Investments, Joanna Popper, Jim Dew, Joe Polish, JLS Fund, Lionheart Ventures,
Read More
Pear Therapeutics Goes Public Via $1.6B SPAC Deal – Digital Health IPO
What You Should Know:
- Pear Therapeutics, the leader in developing and commercializing prescription digital therapeutics to treat serious disease, and Thimble Point Acquisition Corp (Nasdaq: THMA), a special purpose acquisition company (SPAC) whose management team is associated with the Pritzker Vlock Family Office, today announced that they have entered into a definitive business combination agreement.
- Pursuant to the Business Combination Agreement, upon closing of the
Read More
Mental Health App Forms Bond with Users, Marking Key Evolution in Digital Therapeutics
What You Should Know:
- Digital therapeutics company Woebot Health announced its findings to an unprecedented and large-scale industry study that sought to understand whether users of its cognitive-behavioral therapy (CBT)-based conversational agent, Woebot, formed therapeutic alliances (or bonds) with the agent compared to traditional face-to-face therapy and other digital interventions that do not deploy a conversational agent.
- According to the study, the bond that Woebot formed with
Read More
